Navigation Links
Sorrento Therapeutics to Present at Two Healthcare Conferences

SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that Dr. Henry Ji, President and CEO, will present a corporate overview at two upcoming conferences.

Rodman & Renshaw Annual Global Investment Conference
Sorrento is scheduled to present at the Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York, NY on Tuesday, September 10, 2013 at 4:55 PM ET (Room 7.03). Dr. Ji will be available for one-on-one meetings during the conference.

Stifel Healthcare Conference 2013
Sorrento is scheduled to present at the Stifel Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 12, 2013 at 4:25 PM ET (Blaxton Room). Dr. Ji will be available for one-on-one meetings during the conference.

The presentation will be webcast live at and can also be accessed through the investor relations page at A replay of the presentation will be available at and will be archived for 90 days.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Sorrento Therapeutics is also developing proprietary antibody drug conjugates (ADCs) as well as antibody formulated drug conjugates (AfDC) combining its G-MAB® antibodies and anti-tumor agents. On March 7, 2013, we entered into an exclusive option agreement with IgDraSol, Inc., a private company focused on developing oncologic agents for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers.

More information is available at

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and STI undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
2. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
3. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
4. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Sorrento Therapeutics Awarded Third Phase I STTR Grant
10. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
11. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Post Your Comments:
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ... and CEO, will discuss corporate updates at the 27 th ... York on Wednesday, December 2, 2015 at 1 ... Relations, and then the link to the event. Participants should ... to visit the site and download any streaming media software ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
(Date:11/25/2015)... PHILADELPHIA, Pennsylvania , November 25, 2015 ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... -of- Care Continuing Medical Education (CME) ... and medical information products and services, will feature latest diagnostic imaging ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... 25, 2015 , ... On November 23rd 2015 Cozy Products, a ... products business. Cozy Products explains what this means for business moving forward. , The ... Cozy Products business model: to sell personal heaters that reduce energy consumption, are economical ...
Breaking Medicine News(10 mins):